BELITE BIO, INC
BLTE · XNASCIK 1889109fmd_125VVQAXXDV7JRNS2PRS0NZH51Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Dec 31, 2025, 6 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 4 | 7 | 9 | 25 | 30 | 45 |
| Selling, general and administrative | – | – | – | 7 | 10 | 39 |
| Total operating expenses | 6 | 10 | 13 | 32 | 40 | 84 |
| Operating income | (6) | (10) | (13) | (32) | (40) | (84) |
| Interest expense | 0 | – | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 4 | 7 |
| Other non-operating income (expense) | (0) | 0 | 0 | 0 | 4 | 7 |
| Income before taxes | (6) | (10) | (13) | (32) | (36) | (78) |
| Income tax expense | 0 | – | – | 0 | 0 | 0 |
| Net income from continuing operations | (6) | – | – | (32) | (36) | (78) |
| Net income | (6) | (10) | (13) | (32) | (36) | (78) |
| Net income to common shareholders | (6) | (10) | (13) | (32) | (36) | (78) |